Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Childhood Trauma Linked With Higher Odds for Adult Neurological IllsParents of Hospitalized Kids Need More Info on Costs: StudyWhich Kids Are at Highest Risk From COVID?Watch Their Backs -- Don't Overload Those SchoolbagsNeighborhood Gun Violence Means Worse Mental Health for KidsLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company SaysChild Obesity Rose Sharply During PandemicCOVID Vaccines for Kids Under 12 Could Come This Fall: FauciChild Cancers Are Rare, But Here Are Signs to Look ForGetting Kids Eyeglasses Boosts School Grades: StudyEczema Can Take Toll on Child's Mental HealthCOVID Cases Rise Sharply Among Kids as School Year StartsKids Piled on Extra Pounds During PandemicYour Young Child Is Sick: Is it COVID or RSV?As Classes Resume, Some Health Tips From the CDCFDA Warns Against 'Off-Label' Use of Pfizer Vaccine in Younger ChildrenParents' Poll Finds Strong Support for Vaccination of Students, TeachersTeachers' Unions, Doctors Agree: Vaccines, Masks Crucial for Return-to-School4 Out of 10 Parents Have No Plans to Get Child Vaccinated for School: PollCommon Pesticide to Be Banned Over Links to  Problems in ChildrenDiabetes in Pregnancy Tied to Eye Issues in KidsChild Injuries, Deaths Spur Recall of 10 Million Magnet Balls, CubesBabies, Toddlers Spread COVID Faster in the Home Than Teens Do: StudyGet Your Kids on a School-Ready Sleep ScheduleNew Clues to What Triggers Dangerous Syndrome in Kids With COVIDModerna COVID Vaccine Safe, Effective in Teens: StudyU.S. Kids Are Eating More 'Ultraprocessed' FoodsEasy Steps to Get Your Child Ready for the COVID-19 VaccineKeeping Classrooms Safe for Kids With Asthma, AllergiesIs the Delta Variant Hitting Kids Harder?White House Outlines Effort to Vaccinate Young as Schools Start to ReopenAHA News: Protecting Children's Mental Health as They Head Back to SchoolParents' Pot Smoking Means More Colds, Flu for KidsTroubling Rise Seen in Both COVID, RSV Cases Among ChildrenPfizer, Moderna to Expand Vaccine Studies in Young ChildrenCan COVID Transmit Easily on Crowded School Buses?Kids Still Dying From Accidental Exposure to Fentanyl Pain PatchesWhen Are Head Injury Risks Highest for Young Soccer Players?Simple Step Gets More School Kids Eating Their VeggiesSurvey Finds U.S. Parents Split on COVID Vaccination for Kids Under 12Most Parents Clueless About Overuse Dangers to Young Pitchers1.5 Million Kids Worldwide Lost Parent or Other Caregiver to COVID-19Prescriptions for U.S. Kids Declined During PandemicHow Your Kid's Education Could Make You HealthierPediatricians' Group: All School Kids, Staff Should Continue to Wear MasksAny COVID Infection Leaves Strong Antibody Levels in KidsMake Summer Camp Safe for Your Child With Asthma, AllergiesDrowning Deaths for U.S. Kids Have Fallen 38% Since 1999Heart Troubles Ease Over Time in Kids With MIS-CHalf of U.S. Teens Plan to Get COVID Shot, But Can Numbers Go Higher?
Links
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting
Child Development & Parenting: Infants (0-2)
Child Development & Parenting: Early (3-7)

Pfizer, Moderna to Expand Vaccine Studies in Young Children

HealthDay News
by Robert Preidt and Robin Foster
Updated: Jul 27th 2021

new article illustration

TUESDAY, July 27, 2021 (HealthDay News) -- Pfizer and Moderna are expanding trials of their COVID-19 vaccines in children ages 5 to 11, to more closely measure the risk of heart inflammation and other rare side effects that occurred in teens and young adults who received the vaccines.

The companies made the move after the U.S. Food and Drug Administration told them that the initial size and scope of their studies were not enough to detect the rare side effects, according to people familiar with the trials, The New York Times reported.

Those sources said the FDA asked the companies to include 3,000 children ages 5 to 11 in their vaccine studies, which is twice the originally proposed number.

Moderna spokesman Ray Jordan confirmed that the company plans to expand its pediatric trial and expects to seek FDA emergency authorization of its vaccine for that age group in winter 2021 or early 2022, the Times reported.

Pfizer has previously said it expected results for children ages 5 to 11 in September, results for children ages 2-5 soon after, and results for children six months to two years in October or November.

The company had no updates on its timetable, a spokesperson said Monday.

FDA spokeswoman Stephanie Caccomo declined to offer specifics.

"While we cannot comment on individual interactions with sponsors, we do generally work with sponsors to ensure the number of participants in clinical trials are of adequate size to detect safety signals," she told the Times.

In June, the U.S. Centers for Disease Control and Prevention published data showing that the two vaccines may have caused myocarditis and pericarditis (inflammation of the heart or surrounding tissue) in more than 1,200 Americans, including about 500 who were younger than 30. The symptoms typically appeared within two weeks of vaccination and were more common in young men and boys. Most cases were mild, the researchers said.

Dr. Paul Offit, an infectious disease specialist who has served on the CDC's Advisory Committee on Immunization Practices, noted that infection with the coronavirus also carries a major risk.

And if expanding the trials were to cause a delay in authorizing vaccines for pediatric use, he said, that would also put children at risk.

"There's always a human price to pay for knowledge," he told the Times. As for the heart ailments, he said, "It's rare, it's generally short lived and self-resolving. It's also a consequence of natural infection."

The American Academy of Pediatrics reported last week that more than 4 million young children and adolescents have tested positive for the virus and 346 have died since the outset of the pandemic.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on COVID vaccines.


SOURCE: The New York Times



328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net